Lv3
340 积分 2022-09-02 加入
Anti-GPRC5D CAR T-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CAR T-cell therapy: a single-centre, single-arm, phase 2 trial
25天前
已完结
Long-term survival with donor CD19 CAR-T cell treatment for relapsed patients after allogeneic hematopietic stem cell transplantation
1个月前
已完结
Uncommon biphasic CAR-T expansion induces hemophagocytic lymphohistiocytosis-like syndrome and fatal multiple infections following BCMA CAR-T cell therapy: a case report
5个月前
已完结
CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies
5个月前
已完结
Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion
5个月前
已完结
Anti-CD19 and anti-BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem-cell transplantation for high-risk newly diagnosed multiple myeloma
9个月前
已完结
Influence of the number and interval of treatment cycles on cytokine-induced killer cells and their adjuvant therapeutic effects in advanced non-small-cell lung cancer (NSCLC)
10个月前
已完结
Cytokine-induced killer cell therapy for advanced pancreatic adenocarcinoma: A case report and review of the literature
10个月前
已完结
Phenotypic characterization and anti-tumor effects of cytokine-induced killer cells derived from cord blood
10个月前
已完结
皖公网安备34019202002308
